NeoCore Technology Co., Ltd AI Stock Analysis
NeoCore Technology Co., Ltd (4131) AI Stock Analysis
NeoCore Technology Co., Ltd
(TPEx:4131)
The score is held back primarily by financial fundamentals: despite an impressive 2025 revenue breakout and sharply better gross margins, the company has posted losses and negative free cash flow for six consecutive years, while debt rose more than sixfold and equity continues to erode. Technicals compound the caution, with the price trading below all major moving averages and a negative MACD signalling a sustained downtrend. Valuation offers no cushion given negative earnings and no dividend. The investment case rests on whether the 2025 revenue surge proves durable and converts into positive operating cash flow before additional financing is needed.
NeoCore Technology Co., Ltd (4131) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 1.23B
- Dividend Yield
- ―
- Average Volume (3M)
- 18.34K
- Price to Earnings (P/E)
- -37.2
- Beta (1Y)
- 0.07
- Revenue Growth
- 42.88%
- EPS Growth
- -34.50%
- Country
- TW
- Employees
- 44
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
NeoCore Technology Co., Ltd Business Overview & Revenue Model
Company Description
NeoCore Technology Co., Ltd. is primarily engaged in the creation, manufacture, and distribution of biochips and advanced rapid nucleic acid hybridization devices. Their extensive product range features systems designed for food safety screening, hum...
NeoCore Technology Co., Ltd Financial Statement Overview
Summary
Fiscal 2025 was an inflection year: revenue surged roughly four-fold to NT$245 million, gross margin expanded from 5.3% to 35.3%, net loss narrowed to NT$34 million, and cash burn shrank by about two-thirds. However, the company remains unprofitable at every level, with an operating loss of NT$63 million, negative EBITDA, and a sixth straight year of negative operating and free cash flow. Equity has steadily eroded to NT$283 million as losses accumulate, while total debt jumped from NT$24 million to NT$159 million, lifting debt-to-equity from 0.08 to 0.56. The result is a rapidly improving trajectory layered on a still pre-profitability, cash-consuming financial profile that may require further financing.
Income Statement
46NeutralBalance Sheet
52NeutralCash Flow
34Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 277.54M | 244.66M | 61.55M | 64.73M | 88.97M | 88.93M |
| Gross Profit | 110.17M | 86.45M | 3.29M | -9.09M | 11.78M | 19.40M |
| EBITDA | 3.62M | -33.41M | -43.89M | -72.11M | -29.49M | -15.11M |
| Net Income | -34.73M | -34.24M | -48.14M | -64.64M | -28.21M | -17.20M |
Balance Sheet | ||||||
| Total Assets | 581.03M | 549.84M | 340.76M | 548.75M | 266.79M | 281.96M |
| Cash, Cash Equivalents and Short-Term Investments | 76.27M | 114.51M | 207.99M | 299.29M | 46.26M | 39.87M |
| Total Debt | 186.04M | 158.66M | 24.46M | 96.89M | 114.08M | 96.69M |
| Total Liabilities | 274.16M | 248.84M | 35.67M | 197.47M | 185.81M | 164.60M |
| Stockholders Equity | 286.13M | 282.54M | 305.09M | 347.68M | 75.93M | 112.05M |
Cash Flow | ||||||
| Free Cash Flow | -82.25M | -26.30M | -69.66M | -75.42M | -3.43M | -17.15M |
| Operating Cash Flow | -38.54M | -20.67M | -57.15M | -63.88M | -2.69M | -17.15M |
| Investing Cash Flow | 18.81M | -63.21M | -25.17M | -11.69M | 5.51M | 2.50M |
| Financing Cash Flow | 53.43M | -9.61M | -2.97M | 328.60M | 27.06M | -3.44M |
NeoCore Technology Co., Ltd Peers Comparison
Overall Rating
TW:416161Neutral
TW:413348Neutral
TW:410945Neutral- TW:413144Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| TW:4161 | 61Neutral | TWD 1.22B | 11.45 | ― | 3.32% | 7.54% | 35.87% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| TW:4133 | 48Neutral | TWD 1.20B | 27.03 | ― | 0.56% | -4.19% | ― |
| TW:4109 | 45Neutral | TWD 1.21B | 256.25 | ― | 1.95% | 13.00% | 902.22% |
| TW:4131 | 44Neutral | TWD 1.21B | -37.17 | ― | ― | 42.88% | -34.50% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:4131 | NeoCore Technology Co., Ltd | 30.65 | -1.85 | -5.69% | |
| TW:4109 | Jia Jie Biomedical Co., Ltd. | 10.25 | -5.46 | -34.76% | |
| TW:4133 | Abnova Taiwan Corp. | 20.00 | -3.27 | -14.07% | |
| TW:4161 | Bioptik Technology, Inc. | 21.10 | -4.55 | -17.73% | |
| TW:4195 | Genomics BioSci & Tech. Co., Ltd. | 14.90 | -9.70 | -39.43% | |
| TW:7803 | aetherAI Co., Ltd. | 12.50 | -20.20 | -61.77% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026